IMAB Stock Price | I-Mab P/E, Revenue, EPS, & Forecasts

I-Mab • IMAB

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About I-Mab

Ticker

IMAB

Trading on

NASDAQ

ISIN

US44975P1030

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Xi-Yong Fu M.B.A., Ph.D.

Headquarters

2440 Research Boulevard, Rockville, MD, United States, 20850

Employees

Website

i-mabbiopharma.com

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Metrics

BasicAdvanced

Market cap

$534M

P/E ratio

EPS

-$0.51

Dividend Yield

0.00%

Beta

1.46

Forward P/E ratio

EBIDTA

$-38.1M

Ex dividend date

Price & volume

Market cap

$534M

Average daily volume

1.5M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

25.39

Price to book

2.42

Earnings

EPS

-$0.51

EPS estimate (current quarter)

-$0.05

EPS estimate (next quarter)

-$0.05

EBITDA

$-38.1M

Revenues (TTM)

$3.5M

Revenues per share (TTM)

$0.04

Technicals

Beta

1.46

52-week High

$6.79

52-week Low

$0.60

50-day moving average

$4.43

200-day moving average

$2.43

Short ratio

2.01

Short %

3.97%

Management effectiveness

ROE (TTM)

-18.46%

ROA (TTM)

-10.36%

Profit margin

0.00%

Gross profit margin

$41.6M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

-62.10%

Share stats

Outstanding Shares

115M

Float

97.8M

Insiders %

21.40%

Institutions %

21.10%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 5 analysts.

Average price target

$8.60

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.11

-$0.07

-57.14%

Q3 • 24Missed

-$0.06

-$0.05

-20.00%

Q4 • 24Missed

-$0.06

8.33%

Q1 • 25Beat

-$0.07

-$0.04

-75.00%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-3.2M

-∞%

Q1 • 25

$0M

$-5.5M

-∞%

Q2 • 25

NaN%

74.73%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$209M

$10.6M

5.07%

Q1 • 25

$207M

$10M

4.83%

Q2 • 25

-1.07%

-5.90%

-4.88%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

Q1 • 25

Q2 • 25

NaN%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a I-Mab share?

I-Mab shares are currently traded for undefined per share.

How many shares does I-Mab have?

I-Mab currently has 115M shares.

Does I-Mab pay dividends?

No, I-Mab doesn't pay dividends.

What is I-Mab 52 week high?

I-Mab 52 week high is $6.79.

What is I-Mab 52 week low?

I-Mab 52 week low is $0.60.

What is the 200-day moving average of I-Mab?

I-Mab 200-day moving average is $2.43.

Who is I-Mab CEO?

The CEO of I-Mab is Dr. Xi-Yong Fu M.B.A., Ph.D..

How many employees I-Mab has?

I-Mab has 32 employees.

What is the market cap of I-Mab?

The market cap of I-Mab is $534M.

What is the P/E of I-Mab?

The current P/E of I-Mab is null.

What is the EPS of I-Mab?

The EPS of I-Mab is -$0.51.

What is the PEG Ratio of I-Mab?

The PEG Ratio of I-Mab is null.

What do analysts say about I-Mab?

According to the analysts I-Mab is considered a buy.